Documentdetail
ID kaart
doi:10.1038/s42003-024-06097-6...
Auteur
Niu, Liangbo Li, Yi Huang, Guixiang Huang, Wei Fu, Jing Feng, LuLangue
enEditor
Nature
Categorie
Life Sciences
Jaar
2024
vermelding datum
03-04-2024
Trefwoorden
effective resistance cisplatin cancer gastric gc ferroptosis fam120aBeschrijving
N6-methyladenosine modification of FAM120A enhanced cisplatin resistance by inhibiting ferroptosis and targeting FAM120A is an effective strategy to alleviate cisplatin resistance in gastric cancer.
The occurrence of chemoresistance is an inescapable obstacle affecting the clinical efficacy of cisplatin in gastric cancer (GC).
Exploring the regulatory mechanism of cisplatin resistance will help to provide potential effective targets for improving the prognosis of gastric cancer patients.
Here, we find that FAM120A is upregulated in GC tissues and higher in cisplatin-resistant GC tissues, and its high expression is positively correlated with the poor outcome of GC patients.
Functional studies indicate that FAM120A confers chemoresistance to GC cells by inhibiting ferroptosis.
Mechanically, METTL3-induced m6A modification and YTHDC1-induced stability of FAM120A mRNA enhance FAM120A expression.
FAM120A inhibits ferroptosis by binding SLC7A11 mRNA and enhancing its stability.
FAM120A deficiency enhances cisplatin sensitivity by promoting ferroptosis in vivo.
These results reveal the function of FAM120A in chemotherapy tolerance and targeting FAM120A is an effective strategy to alleviate cisplatin resistance in GC.
Niu, Liangbo,Li, Yi,Huang, Guixiang,Huang, Wei,Fu, Jing,Feng, Lu, 2024, FAM120A deficiency improves resistance to cisplatin in gastric cancer by promoting ferroptosis, Nature
Choice Between Partial Trajectories: Disentangling Goals from Beliefs
agents models aligned based bootstrapped learning reward function model return choice choices partial
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review
aes medications bta incidence migraine drugs disorders
